Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESILIENT: Taldefgrobep alfa in ambulatory and non-ambulatory spinal muscular atrophy
2022-000193-25Phase 3Active
- Sponsor
- Biohaven Ltd.
- Start
- Jul 2022
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in spinal muscular atrophy (SMA) comparing Taldefgrobep alfa with Placebo (2 arms). Primary endpoint: Change from baseline in MFM-32 total score at Week 48. Started Jul 2022; status: active.
02
Drugs
taldefgrobep alfa
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on 2022-000193-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000193-25.